Clinical Trial: Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of AT1001 in Patients With Fabry Disease

Brief Summary: This is a long term open label study of AT1001 in patients with Fabry disease previously enrolled in a Phase 2 AT1001 trial.

Detailed Summary: This is a long term open label study of AT1001 in patients with Fabry disease previously enrolled in a Phase 2 AT1001 trial. Patients will return to the study center approximately every 3 months for safety evaluations including physical exam, blood and urine tests.
Sponsor: Amicus Therapeutics

Current Primary Outcome: Long term safety and outcomes measures assessed at each visit. [ Time Frame: Long term ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Amicus Therapeutics

Dates:
Date Received: September 5, 2007
Date Started: September 2007
Date Completion:
Last Updated: December 19, 2013
Last Verified: December 2013